Gregg L. Semenza, M.D., Ph.D.
Dr. Semenza is Director of the Vascular Program in the Johns Hopkins Institute for Cell Engineering and Professor in the Deparments of Pediatrics, Medicine, Oncology, Radiation Oncology and McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine.
Within the past three years, Dr. Semenza has served as a consultant to Cell Therapeutics Inc., EntreMed Inc., Johnson & Johnson Pharmaceutical Services, Merck and Company, Novartis Pharmaceuticals and Threshold Pharmaceuticals. Under a licensing agreement between Genzyme Corporation and the Johns Hopkins University, Dr. Semenza is entitled to a share of fees received by the University from sales of HIF-1a gene therapy technology that is described in this review. Terms of this arrangement are managed by the University in accordance with its conflict-of-interest policies.
Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.
Estimated time to complete:
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- Discuss the molecular mechanisms by which changes in cellular PO2 are sensed and transduced to changes in gene expression through the activity of HIF-1
- Discuss the role of HIF-1 and its downstream gene products in mediating adaptive responses to tissue ischemia and relevant translational research
- Discuss the role of HIF-1 in the pathogenesis of cancer and relevant translational research.